CARBOGEN AMCIS will Provide Liposomal Formulation for Highly Potent Drugs through Alliance19 October 2011
BUBENDORF, Switzerland (October 19, 2011) — Today, Switzerland-based CARBOGEN AMCIS AG, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company, announced the signing of a strategic alliance agreement with Polymun Scientific GmbH, an Austrian private company that specializes in liposomal formulations and biopharmaceuticals for application in humans.
The strategic alliance agreement gives CARBOGEN AMCIS access to Polymun’s innovative liposome technology for the formulation of APIs, while Polymun receives access to CARBOGEN AMCIS’ expertise in the development and manufacture of highly potent APIs.
"We believe that our customers are interested in finding new ways to better deliver highly potent active ingredients. This alliance expands our portfolio of offerings and moves us one step closer to achieving this goal." said Mark Griffiths, CEO of CARBOGEN AMCIS. "CARBOGEN AMCIS and Polymun look forward to combining both companies’ strengths to offer our customers new cost-effective solutions for liposomal formulation of highly potent drugs."
The agreement with CARBOGEN AMCIS provides Polymun with a reliable partner for the handling of highly potent APIs and allows Polymun to expand its service offerings to cytotoxics and cytostatics.
"We are extremely excited to be partners with CARBOGEN AMCIS, a leading company providing state-of-the-art containment services. This alliance provides both companies with a full-range of liposomal formulation services for highly potents for clinical trials and commercial applications." said Dr. Dietmar Katinger, CEO of Polymun.
CARBOGEN AMCIS AG (www.carbogen-amcis.com) is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development, allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.
Polymun Scientific Immunbiologische Forschung GmbH (www.polymun.com) is a private company founded in 1992 by Prof. Dr. Hermann Katinger, located in Klosterneuburg, Austria. The company offers contract development and manufacturing services for biopharmaceuticals, using both mammalian and microbial cell technology. In addition, the company offers innovative liposome technology for the formulation of pharmaceutically active ingredients and vaccine antigens. Polymun operates in accordance with current GMP guidelines and holds an Austrian production license for pharmaceuticals thus meeting the EU requirements for drug manufacturing.
Dishman Group (www.dishmangroup.com) is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and commercial API manufacturing services. Dishman Group improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe, China and India.